An observational study in Endometriosis, sponsored by Li Li. Recruiting at 1 site in China. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-06.
Sponsored by Li Li · Observational
Among 47 studies in Endometriosis with a site in China — 16 open to participants now, 17 under way, 2 of them phase 3. Endometriosis · China.
Among the 47 studies in Endometriosis with a site in China, this one is the 7th largest by planned enrollment of the 19 observational ones, is one of 6 that started in 2026, is one of 19 observational ones, reaches primary completion later than 14 of the 16 other live ones, and was the 45th registered.
920 studies on the registry are indexed under Endometriosis; 266 are open to participants now.
This study's planned enrollment of 716 is above the median of 135 across 349 observational studies indexed under Endometriosis.
Browse Endometriosis studies →16 of the 47 studies in Endometriosis with a site in China are open now, in 1 country. Each count lists the studies.
Of the 176 Endometriosis studies recruiting now, 51 (29%) set no upper age limit and 123 (70%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.
This study: 18 Years to 45 Years · female · healthy volunteers too.
The full table on the hub →47 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 6 started in 2026.
Median enrollment 161 across the 28 interventional studies, 402 across the 19 observational. Of the 16 that completed or were terminated, 3 (19%) have results posted.
20 of 47 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Li Li as lead sponsor.
Li Li has 1 study filed under Endometriosis — fewer than ten, so there is no comparison to draw.
6 of the studies in Endometriosis with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07860203Catherin ZhangStellate Ganglion Block and Dexmedetomidine for Postoperative Sleep in Women Undergoing Laparoscopic Gynecologic Surgery | 2026-12 |
| NCT06266897Zhujiang HospitalA Study on the Correlation Between Endometriosis and Intra-tissue Microbiota | 2026-12 |
| NCT07014761Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityThe Influence of Central Sensitization in Endometriosis Disease | 2027-03-31 |
| NCT07755956Zhuhai Huahaikang Pharmaceutical Technology Co., Ltd.Phase Ia Trial of HHK001 Compared With Enantone in Patients With Endometriosis | 2027-03-31 |
| NCT06584760The Fourth Affiliated Hospital of Zhejiang University School of MedicineResearch on the Impact of Chronic Pelvic Pain on Endometriosis | 2027-09 |
Among the 47 studies in Endometriosis with a site in China, from their registry updates:
Endometriosis is a chronic condition that may cause pelvic pain, ovarian cysts, infertility, and recurrent symptoms. This prospective observational cohort study will enroll women aged 18 to 45 years with endometriosis and age- and body mass index-matched healthy women. Participants will receive routine clinical care, and the study will not assign medications or procedures. Baseline clinical information will be collected, and participants will be followed for 24 months, every 3 months during the first year and every 6 months thereafter. The study will assess cyst recurrence, pain recurrence, pregnancy and live birth outcomes, and other long-term clinical outcomes. It will also evaluate associations between disease characteristics, rASRM stage, routine medical treatment, and subsequent clinical and reproductive outcomes, and will support the establishment of an endometriosis clinical research database.
This is a prospective observational cohort study designed to characterize the clinical course and reproductive outcomes of women with endometriosis. The study will prospectively enroll women aged 18 to 45 years with a clinical, imaging, or surgical diagnosis of endometriosis. Age- and body mass index-matched healthy women with regular menstrual cycles may also be enrolled as a control cohort.
Baseline data will include demographic characteristics, reproductive history, lifestyle factors, clinical symptoms, pain scores, disease phenotype, lesion characteristics, rASRM stage, previous surgery, laboratory findings, ovarian reserve indicators, and assisted reproductive treatment information, when applicable. Treatments received as part of routine clinical care, including gonadotropin-releasing hormone agonists and progestogens, will be recorded as observational exposures. The study protocol will not assign participants to a specific medication, procedure, or assisted reproductive treatment.
Participants will be followed for 24 months. Follow-up assessments will be conducted every 3 months during the first year and every 6 months thereafter, with clinically important outcome events recorded when they occur. Outcomes of interest include cyst recurrence, pain recurrence, pregnancy outcomes, live birth, and other long-term clinical complications.
Associations between baseline clinical characteristics, disease severity, routine treatment patterns, and subsequent outcomes will be evaluated using appropriate descriptive and multivariable statistical methods. Time-to-event outcomes may be analyzed using Kaplan-Meier methods and Cox proportional hazards regression, with adjustment for potential confounding factors.
Women aged 18 to 45 years receiving evaluation or clinical care for endometriosis at Guangdong Women and Children Hospital will be prospectively recruited into the endometriosis cohort. Age- and body mass index-matched healthy women with regular menstrual cycles will be recruited as a comparison cohort. Participants will be followed for 24 months according to the study protocol.
Inclusion Criteria:
Female participants aged 18 to 45 years. Able and willing to provide written . For the endometriosis cohort: diagnosis of endometriosis based on clinical findings, imaging, and/or laparoscopy.
For the endometriosis cohort: availability of complete baseline clinical data, including revised American Society for Reproductive Medicine stage and lesion type.
For the healthy control cohort: healthy women matched by age and to participants in the endometriosis cohort.
For the healthy control cohort: regular menstrual cycles of 28 to 30 days.
Exclusion Criteria:
For the endometriosis cohort: concurrent malignant tumor or severe cardiac, hepatic, or renal disease.
For the endometriosis cohort: previous hysterectomy. For the endometriosis cohort: a mental disorder that prevents adherence to study follow-up.
Exclusion Criteria:
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Women aged 18 to 45 years with endometriosis diagnosed based on clinical findings, imaging, and/or laparoscopy will be prospectively enrolled and followed for 24 months. Baseline disease characteristics, routine clinical treatments, pain outcomes, cyst recurrence, and reproductive outcomes will be recorded.
Age- and body mass index-matched healthy women aged 18 to 45 years with regular menstrual cycles of 28 to 30 days will be prospectively enrolled as a comparison cohort.
Endometriosis-Related Pain Recurrence
The number and percentage of participants in the endometriosis cohort who experience recurrence of endometriosis-related pain during follow-up. Pain severity will be assessed using a visual analogue scale and clinical symptom records
Time frame: From enrollment through 24 months
Endometriosis-Related Cyst Recurrence
The number and percentage of participants in the endometriosis cohort with a recurrent endometriosis-related cyst documented during follow-up.
Time frame: From enrollment through 24 months
Live Birth During Follow-Up
The number and percentage of participants in the endometriosis cohort with a live birth during follow-up. Live birth is defined as delivery of a live infant at 28 gestational weeks or later.
Time frame: From enrollment through 24 months
Plan to share: No
Started Feb 2026 (actual). Primary completion is estimated for Jul 2029, 41 months after the start.
Of 155 non-industry observational studies under Endometriosis, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's planned 41 months is above that.
Counting every sponsor, half of 182 studies reached it within 30 months; a quarter within 14 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.